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Background: Lysine-specific demethylase 1(LSD1) is implicated in the tumorigenesis and progression in various
cancers. However, the expression of LSD1 in epithelial ovarian cancer and its clinical significance has not been
examined in detail.
Methods: Immunohistochemical was used to detect the expression of LSD1 in normal ovarian epithelial tissues,
cystadenoma, borderline cystadenoma, and cystadenocarcinoma. Next, the correlations between expression of
LSD1 and clinicopathological features was assessed in 96 species of serous cystadenocarcinoma and 36 species of
mucinous cystadenocarcinoma.
Results: Immunohistochemical results showed that the expression of LSD1 was gradually increased from benign
cystadenoma and borderline cystadenoma to cystadenocarcinoma. The positive ratio of LSD1 expression was
50% in normal ovarian epithelial tissues, 72% in serous cystadenoma, 73% in mucinous cystadenoma, 82% in
borderline serous cystadenoma, 83% in borderline mucinous cystadenoma, 94% in serous cystadenocarcinoma
and 92% in mucinous cystadenocarcinoma, respectively. LSD1 expression levels were associated with
International Federation of Gynecology and Obstetrics stage and lymphatic metastasis in both serous and mucinous
cystadenocarcinoma samples. Kaplan-Meier curves suggested that overall survival time of patients with high LSD1
expression was significantly shorter than that of patients with low LSD1 expression. Multivariate Cox proportional
hazard regression indicated that higher LSD1 expression was a significant independent predictor of poor survival of
EOC patients (P = 0.016).
Conclusions: These results suggest that LSD1 may be involved in carcinogenesis and progression with promising
therapeutic potential for epithelial ovarian cancer.
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cystadenocarcinomaIntroduction
Ovarian cancer is the second most common gyneco-
logic cancer and ranks the most lethal gynecological
malignancy in the world, due to its high incidence
of metastasis and high relapse rate [1]. The vast
majority of ovarian cancer will be epithelial ovarian
cancer (EOC), which comprises three major histo-
logical subtypes (serous, mucinous, and endometrioid).* Correspondence: yangchunqingnj@163.com; xffang@zju.edu.cn
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unless otherwise stated.Unfortunately, the most of EOC patients were diagnosed
at FIGO (International Federation of Gynecology and
Obstetrics stage) III/IV stage and had unfavorable
prognosis, with a frustrating 5-year overall survival
(<50%) [2]. Although the molecular alterations in EOC
have been widely studied, studying the mechanism that
regulates the initiation and progression will provide fur-
ther insights into the development and progression of
EOC.
Lysine-specific demethylase 1 (LSD1) is the first his-
tone demethylase to be discovered [3]. Overexpression
of LSD1 has also been associated with unfavourablehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in numerous tumors, such as hepatocellular carcin-
oma, colon cancer, breast cancer, prostate cancer, and
non-small cell lung cancer [4-8]. Recently, one study
showed that the expression of LSD1 mRNA was in-
creased in ovarian tumors and LSD1 mRNA was overex-
pressed in stage IIIC and high-grade ovarian tumors
[9]. However, the expression and significance of LSD1
protein in EOC is still poorly understood.
This study was to systematically investigate LSD1
protein expression in normal ovarian epithelium, benign
cystadenoma, borderline cystadenoma, and cystadenocar-
cinoma using immunohistochemical (IHC) staining.
The potential correlation between the expression level
of LSD1 and clinicopathological features of EOC was
also analyzed.Materials and methods
Tissue specimens
The specimens (n = 407) were randomly obtained from
patients with complete clinical data in the Pathological
Department of Jiangsu Province Hospital and Second
Affiliated Hospital of Zhejiang University College of
Medicine between March 2000 and May 2013. All pa-
tients were evaluated for histological type and graded
by the two gynecological pathologists. The samples
consisted of 50 normal ovarian epithelia species; 199
species of serous epithelial lesions, and 158 species of
mucinous epithelial lesions. None of the patients were
treated with chemotherapy, immunotherapy or radio-
therapy prior to specimen collection. Tissue samples
were obtained after patients’ written informed consent
under a general tissue collection protocol approved by
The Research Ethics Committee of Jiangsu Province
Hospital and The Research Ethics Committee of
Second Affiliated Hospital of Zhejiang University
College of Medicine.Figure 1 LSD1 expression in positive control and negtive control. (A) A lun
positive control. (B) “No primary antibody” including everything but the pr
adenocarcinomas tissue sample.Immunohistochemistry
The immunohistochemistry (IHC) for LSD1 (1:100;
Cell Signaling Inc., Danvers, MA, USA) was performed
on formalin-fixed, paraffin-embedded tissue sections using
steam heatinduced epitope retrieval and the DAB chromo-
gen (Boster, Wuhan, China). Positive cells were indicated
by the presence of brown staining in the nucleus. The
LSD1 expression was evaluated based on intensity of
staining and distribution of positive cells. Both the
percentage of positive cells and the staining intensity
were evaluated under double-blind conditions. The
percentage positivity was scored as four classes: “0”
(<5%, negative), “1” (5–25%, sporadic), “2” (25–50%,
focal), or “3” (>50%, diffuse). The staining intensity
was scored as “0” (no staining), “1” (weakly stained), “2”
(moderately stained), or “3” (strongly stained). The LSD1
immunostaining score was calculated as the percentage
positive score × the staining intensity score and ranged as 0,
1, 2, 3, 4, 6, and 9. The sum-indexes (−), (+), (++),
and (+++) indicated overall staining score of 0, 1–3,
4–6, and 9, respectively. For statistical analysis, sum-
indexes (−) and (+) were defined as low LSD1 expression,
while sum-indexes (++) and (+++) were defined as high
LSD1 expression.
Statistical analysis
Statistical analysis was carried out using SPSS version
16.0. LSD1 expression in different groups was analyzed
using the non-parametric tests. The approximate normal
distribution of the two groups is represented as Z-score.
The correlation between LSD1 expression and the
clinicopathological features was assessed by chi-square
test. Survival analyses were performed using the log-rank
test and Kaplan-Meier plots approach. Variables with
P value < 0.05 in univariate analysis were used in
thesubsequent multivariate analysis on a basis of Cox
proportionalhazards model. For all analyses, the level
of significance was set at P < 0.05.g adenocarcinomas that overexpression of LSD1 was as uesed as
imary antibody showed negtive stain of LSD1 in the same lung
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Expression of LSD1 in ovarian epithelial lesions
A lung adenocarcinomas that overexpression of LSD1
was as uesed as positive control as shown in Figure 1A.
“No primary antibody” control showed negative stain ofFigure 2 LSD1 expression and localization in (A) normal ovarian epith
and (D) serous cystadenocarcinoma (20×, bar = 100 μm). The Higher m
(E, G, F, H).LSD1 in the same lung adenocarcinomas tissue sample
(Figure 1B). IHC staining revealed that LSD1 was localized
mainly to the cell nucleus (dark brown nuclei) in different
ovarian epithelial lesions (Figures 2 and 3). Positive IHC
staining of LSD1 was observed in 50% of normal ovarianelia, (B) serous cystadenoma, (C) borderline serous cystadenoma,
agnification (40×, bar = 1 μm) was shown as the right image
Figure 3 LSD1 expression and localization in (A) normal ovarian epithelia, (B) mucinous cystadenoma, (C) borderline mucinous
cystadenoma, and (D) mucinous cystadenocarcinoma (20×, bar = 100 μm). The Higher magnification (40×, bar = 1 μm) was shown
as the right image (E, G, F, H).
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cystadenoma, 82% of borderline serous and mucinous
cystadenoma, 94% of serous cystadenocarcinoma, and
92% of mucinous cystadenocarcinoma, respectively (Table 1).
LSD1 expression was significant statistical differencebetween the normal ovarian epithelia and all of carcinomas
(benign, borderline tumors and carcinomas; P < 0.001). In
additional, the incidence of LSD1 detected in epithelial
carcinomas was significantly higher than that in benign
and borderline tumors, both in subtypes of serous and
Table 1 Expression of LSD1 in different ovarian epithelial lesions and normal ovarian epithelia
Clinicopathological features Cases (N) LSD1 Positive (%) P
— + ++ +++
Normal ovarian epithelia 50 25 20 5 0 50 0.000ab
Serous epithelial lesions Serous cystadenoma 53 15 25 10 3 72 0.010c
Borderline serous cystadenoma 50 9 10 25 6 82 0.000d
0.002i
Serous cystadenocarcinoma 96 6 9 31 50 94 0.000ejk
Mucinous epithelial lesions Mucinous cystadenoma 59 16 25 16 2 73 0.003f
Borderline mucinous cystadenoma 63 11 17 29 6 83 0.000g
0.009l
Mucinous cystadenocarcinoma 36 3 5 9 19 92 0.000hmn
aNon-parametric Jonckheere-Terpstra test, P value of normal and serous groups.
bNon-parametric Jonckheere-Terpstra test, P value of normal and mucinous groups.
cnormal ovarian epithelia versus serous cystadenoma; Z = −2.587, P = 0.010.
dnormal ovarian epithelia versus borderline serous cystadenoma; Z = −5.068, P = 0.000.
enormal ovarian epithelia versus serous cystadenocarcinoma; Z = −8.404, P = 0.000.
fnormal ovarian epithelia versus mucinous cystadenoma; Z = −3.000, P = 0.003.
gnormal ovarian epithelia versus borderline mucinous cystadenoma; Z = −5.073, P = 0.000.
hnormal ovarian epithelia versus mucinous cystadenocarcinoma; Z = −6.277, P = 0.000.
iserous cystadenoma versus borderline serous cystadenoma; Z = −3.126, P = 0.002.
jserous cystadenoma versus serous cystadenocarcinoma; Z = −7.106, P = 0.000.
kborderline serous cystadenoma versus serous cystadenocarcinoma; Z = −4.735, P = 0.000.
lmucinous cystadenoma versus borderline mucinous cystadenoma; Z = −2.611, P = 0.009.
mmucinous cystadenoma versus mucinous cystadenocarcinoma; Z = −5.146, P = 0.000.
nborderline mucinous cystadenoma versus mucinous cystadenocarcinoma; Z = −3.824, P = 0.000.
Z= Z-score.
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was gradually increased from benign and borderline
to malignant ovarian tumors, suggusting that LSD1
protein was up-regulated in the development of serous or
mucinous ovarian epithelial carcinoma.
Association of LSD1 expression with clinicopathological
features of EOC patient
The correlation between LSD1 expression in ovarian
carcinomas detected by IHC and clinicopathological
features was further analyzed, including age, FIGO
stage, tumor grade, lymphatic metastasis status and
peritoneal cytology. The results showed that LSD1
expression was correlated with FIGO stage (P = 0.006)
and lymph node metastasis (P = 0.001) among serous
tumors (Table 2). Among mucinous tumors, significant
association was also found between LSD1 expression
and FIGO stage (P = 0.037) and lymph node metastasis
(P = 0.026).
Up-regulation of LSD1 is associated with poorer
prognosis of EOC patient
The potential correlation between expression of LSD1
and EOC prognosis was addressed in the present
study. Patients were classified into low LSD1 expres-
sion group and high LSD1 expression group accord-
ing to the IHC results. Kaplan-Meier curves
suggested that overall survival time of patients withhigh LSD1 expression was significantly shorter than
that of patients with low LSD1 expression (P = 0.0006;
Figure 4). Cox regression analyses were then con-
ducted to analyze various prognostic parameters for
survival of EOC patients. Univariate analysis identified
three prognostic factors: FIGO stage (I, II, III, IV),
lymphatic metastasis (negative, positive) and LSD1
expression (high, low). In multivariate Cox propor-
tional hazard regression, LSD1 higher expression was
a significant independent predictor of poor survival of
EOC patients (P = 0.016), as well as FIGO stage (P = 0.019)
(Table 3).
Discussion
Epigenetic alteration by histone methylation or demeth-
ylation has been shown to play an essential role in
carcinogenesis and cancer progression. The methylation
status of histone demethylases plays an important role in
the regulation of gene expression [10]. Inhibition of chro-
matin modifying enzymes such as histone demethylases is
a potential therapeutic strategy to inhibit cancer growth
[11]. LSD1 had been found to control gene expression by
histone modification. LSD1 is described as the first identi-
fied histone demethylase which represses and activates
transcription by specifically demethylating the methyl
groups from mono- and di-methylated Lysine (Lys)4 of
histone H3K4me and Lys9 of H3K9me [3,12]. Previous
studies showed that LSD1 was aberrantly overexpressed in
Table 2 Correlations between expression of LSD1 and clinicopathological features
Diagnosis Characteristics Cases (N) IHC results of LSD1 (N) p-value
Low High
Serous cystadenocarcinoma Age 0.352
≦60 40 19 21
>60 56 30 26
FIGO stage 0.006
I 7 4 3
II 23 5 18
III 54 4 50
IV 12 2 10
Tumor grade 0.707
I 30 6 24
II 32 4 28
III 34 5 29
Lymphatic metastasis 0.001
Negative 25 9 16
Positive 71 6 65
Peritoneal cytology
Negative 46 20 26 0.152
Positive 50 30 20
Mucinous cystadenocarcinoma Age 0.179
≦60 16 6 10
>60 20 13 7
FIGO stage 0.037
I 6 4 2
II 9 3 6
III 12 1 11
IV 9 0 9
Tumor grade 0.995
I 9 2 7
II 14 3 11
III 13 3 10
Lymphatic metastasis 0.026
Negative 11 5 6
Positive 25 3 22
Peritoneal cytology 0.311
Negative 15 9 6
Positive 21 8 13
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associated with more aggression in breast cancer, prostate
cancer, and lung cancer [5-7].
Only one study showed that overexpression of LSD1
mRNA in stage IIIC and high-grade ovarian tumors with
the likely exception of mucinous tumors [9]. The higherlevels of LSD1 mRNA was observed in serous, papillary
serous, endometrioid, and clear cell tumors, but not in
those of the mucinous subtype. The mucinous group in
that cohort they studied consists of only a small number
of tumors (n = 5). In our study, IHC results showed
that higher expression of LSD1 protein in both serous
Figure 4 Overexpression of LSD1 predicts poor clinical outcome
of EOC. Kaplan-Meier curves for overall survival according
to expression of LSD1 in 132 EOC patients. (Log rank
test, P = 0.0006).
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ovarian tissue. We think this inconsistence is due to realtive
larger number of mucinous cystadenocarcinoma (n = 36)
detected in our study. In additional, diffrennt detection
methods also contribute to the inconsistent results. Our
results also showed that LSD1expression was increased
with advanced FIGO stage, but not with tumor grade. High
LSD1 expression was also associated with advanced tumor
stage of pancreatic cancer but not tumor grade [13]. Our
results indicated that high LSD1 expression was associated
with more aggressive biological behavior. In fact, our
results showed that LSD1 expression was correlated
with lymph node metastasis among ovian tumors.
There was also significant statistical difference of LSD1
protein expression between benign tumor groups and
the normal groups. Therefore, LSD1 is potential to be
an early diagnostic marker for serous or mucinous
cystadenocarcinoma.
Furthermore, we found that the expression of LSD1 was
gradually increased from benign and borderline tumors to
epithelial carcinomas in a stepwise manner, both in
subtypes of serous and mucinous, suggesting that LSD1Table 3 Univariate and multivariate Cox regression analyses o
EOC patients
Characteristic Univariate analysis HR (95
Age (y) ≤60, >60 2.661(0.930-5.168)
FIGO stage I, II, III, IV 2.168(1.291-3.686)
Lymphatic metastasis negative, positive 2.196(1.332-5.926)
Peritoneal cytology negative, positive 1.566 (0.566-5.861)
Tumor grade I, II, III 1.265(0.661-2.256)
LSD1 expression low, high 2.233(1.129-5.688)
HR, Hazard ratio; CI, Confidence interval. Statistical significance. *P < 0.05; **P < 0.01protein was up-regulated in the development of serous
and mucinous ovarian epithelial carcinoma. So upregula-
tion of LSD1 may be an early tumor promoting event in
EOC. Previous reports also supported that LSD1 acts as an
early tumor promoter in carcinogenesis through chromatin
regulation [11,14-16]. LSD1 could repress p53 activity
through demethylation of Lys370 in p53, thus inhibit p53-
mediated apoptosis and contribute to carcinogenesis [14].
Upregulation of LSD1 has also been considered as an early
tumor promoting event in breast carcinoma [15]. There is a
gradual increase of LSD1 expression within tumor progres-
sion from pre-invasive ductal carcinoma in situ to invasive
ductal breast carcinoma [15]. Interruption of LSD1 by
using siRNA or chemical inhibitor could suppress cancer
cell proliferation, migration and invasion in various
cancers [7,17-20] LSD1 knockout colorectal cancer
cells showed less tumorigenic both in vivo and in vitro
[21]. Chemical LSD1 inhibition could cause cytotoxicity in
ovarian cancer lines [9]. Thus, our results indicate that
LSD1 may be involved in the carcinogenesis and progres-
sion of EOC. The concrete mechanism in which LSD1 is
linked to EOC development is deserved to been further
explored.
IHC results also showed that higher expression
LSD1 was associated with FIGO stage or lymphatic
metastasis in both ovarian serous cystadenocarcinoma
and mucinous cystadenocarcinoma. Of note, we
found that EOC patients with high LSD1 expression
had shorter overall survival time than patients with
low LSD1 expression. Importantly, the Cox regression
analyses identified LSD1 expression as a novel pre-
dicting factor for overall survival of EOC patients. It
indicates that LSD1 expression may serve as a novel
prognostic marker for EOC patients, and high LSD1
expression may promote tumor metastasis and associ-
ate with poor survival in ovarian epithelial carcinoma
patients.
In conclusion, our results indicate that LSD1 is involved
in carcinogenesis and progression in EOC. LSD1 may be
an early identification and prognosis marker of EOC with
promising therapeutic potential.f clinicopathologic characteristics for overall survival in
% CI) P value Multivariate analysis HR (95% CI) P value
0.169
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